Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Kantarjian

Showing results (1-10 of 356) with videos related to

Pageof 36
Sort By:
Seminars in Hematology|January 6, 2000
New developments in the treatment of acute myeloid leukemia: focus on topotecanH Kantarjian
Seminars in Hematology|October 21, 1998
New advances in the treatment of hematologic malignancies: focus on topoisomerase I inhibitors. IntroductionH Kantarjian
Annals of Internal Medicine|May 1, 1995
Low-dose interferon-alpha in chronic myeloid leukemiaM Talpaz, H Kantarjian
Seminars in Hematology|January 6, 2000
Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, H Kantarjian
American Journal of Clinical Oncology|October 1, 1987
Implications of cytogenetic findings in secondary leukemiaH Kantarjian, R Walters
Leukemia & Lymphoma|May 30, 2001
Is myelodysplastic related acute myelogenous leukemia a distinct entity from de novo acute myelogenous leukemia? Potential for targeted therapiesC Rosenfeld, H Kantarjian
Seminars in Hematology|October 21, 1998
Topotecan in the treatment of hematologic malignanciesM Beran, H Kantarjian
Leukemia|January 23, 2004
Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study groupH Kantarjian, J Cortes
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2015
Health care in the United States--basic human right or entitlement?G H Jones, H Kantarjian
Leukemia & Lymphoma|May 9, 2001
Idiopathic thrombocytopenic purpura following successful treatment of acute lymphoblastic leukemiaN M Tannir, H Kantarjian
Pageof 36

Showing results (1-10 of 356) with videos related to

Sort By:
Pageof 36
Seminars in Hematology|January 6, 2000
New developments in the treatment of acute myeloid leukemia: focus on topotecanH Kantarjian
Seminars in Hematology|October 21, 1998
New advances in the treatment of hematologic malignancies: focus on topoisomerase I inhibitors. IntroductionH Kantarjian
Annals of Internal Medicine|May 1, 1995
Low-dose interferon-alpha in chronic myeloid leukemiaM Talpaz, H Kantarjian
Seminars in Hematology|January 6, 2000
Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, H Kantarjian
American Journal of Clinical Oncology|October 1, 1987
Implications of cytogenetic findings in secondary leukemiaH Kantarjian, R Walters
Leukemia & Lymphoma|May 30, 2001
Is myelodysplastic related acute myelogenous leukemia a distinct entity from de novo acute myelogenous leukemia? Potential for targeted therapiesC Rosenfeld, H Kantarjian
Seminars in Hematology|October 21, 1998
Topotecan in the treatment of hematologic malignanciesM Beran, H Kantarjian
Leukemia|January 23, 2004
Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study groupH Kantarjian, J Cortes
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2015
Health care in the United States--basic human right or entitlement?G H Jones, H Kantarjian
Leukemia & Lymphoma|May 9, 2001
Idiopathic thrombocytopenic purpura following successful treatment of acute lymphoblastic leukemiaN M Tannir, H Kantarjian
Pageof 36